Key Takeaways:
- AstraZeneca will pay Insitro $40 million upfront for AI-driven drug discovery.
- The partnership targets severe liver disease and heart muscle disorders.
- Insitro could earn up to $1.46 billion in milestone payments, plus royalties.
AstraZeneca strikes a partnership with U.S.-based biotechnology company insitro in a multiyear, $40 million upfront deal to identify and develop treatments for difficult-to-treat liver and heart conditions using artificial intelligence.
The agreement could provide insitro with up to $1.46 billion in development and commercial milestone payments, along with royalties on future sales. AstraZeneca will fund and manage subsequent clinical trials, while insitro will use its AI platform to identify promising drug targets.
AI platform targets hard-to-treat diseases
The collaboration AstraZeneca strikes will focus on metabolic dysfunction-associated steatohepatitis, or MASH, a serious liver disease, and cardiomyopathies, a group of disorders affecting the heart muscle. Researchers have struggled to develop effective treatments for these conditions partly because their underlying biological causes remain difficult to identify.
Insitro will use its Virtual Human platform, which combines lab-grown cell models with machine learning, to investigate disease biology and identify potential treatment targets. The company will advance targets selected by AstraZeneca from early discovery through the development-candidate stage.
A development candidate is a potential drug selected for further testing before clinical trials. The approach aims to help researchers identify promising medicines earlier and reduce uncertainty during drug discovery.
AstraZeneca sees AI speeding drug research
Sharon Barr, executive vice president of biopharmaceuticals research and development at AstraZeneca, said identifying new targets remains one of the industry’s biggest research challenges.
“Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development,” Barr told Reuters.
She explained that researchers can lose an advantage when potential biological targets become widely known through scientific publications. Identifying previously unknown connections and testing them in cellular systems could help researchers investigate new treatment opportunities earlier.
Barr also said combining AI tools with experienced scientists could reduce the number of molecules that researchers need to test in laboratories. The approach may help reduce guesswork and accelerate the search for effective medicines, although the resulting drug candidates must still undergo further testing.
Insitro expands pharmaceutical partnerships
The agreement adds to insitro’s growing collaborations with major pharmaceutical companies. The California-based biotechnology company has also expanded its partnership with Bristol Myers Squibb to investigate additional targets for amyotrophic lateral sclerosis, a progressive disease that affects nerve cells controlling voluntary movement.
Insitro has separately partnered with Eli Lilly to develop AI models that predict how small molecules behave in living organisms. These collaborations reflect pharmaceutical companies’ growing interest in using computational tools and biological models to improve early-stage drug discovery.
Under the deal AstraZeneca strikes, the British pharmaceutical company will take responsibility for funding and conducting future clinical trials. Those studies will be necessary to evaluate the safety and effectiveness of any resulting drug candidates.
The financial agreement includes a $40 million upfront payment, potential milestone payments of approximately $1.46 billion, and a single-digit percentage of future sales in royalties. The milestone payments depend on achieving specified development and commercial goals, rather than representing guaranteed revenue for Insitroo.
The partnership highlights how pharmaceutical companies are exploring AI to identify promising drug targets and improve research efficiency. However, whether the collaboration produces approved treatments will depend on the results of subsequent research and clinical testing.
